Mortality at any time point · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in mortality at any time point compared with deferoxamine (low certainty).
1 finding from 1 review
Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia
1 finding from 1 review
LIC · people with transfusion‐dependent thalassemia
1 finding from 1 review
Satisfaction · people with transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: discontinuations compared with deferiprone (low certainty).
1 finding from 1 review
Renal failure · people with transfusion‐dependent thalassemia
1 finding from 1 review
Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw) · people with transfusion‐dependent thalassemia
Deferasirox probably leads to lower responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw) compared with deferoxamine (moderate certainty).
1 finding from 1 review
Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia
1 finding from 1 review
Change in LIC (mg Fe/g dw) evaluated by biopsy or SQUID · people with transfusion‐dependent thalassemia
1 finding from 1 review
Mortality at any time point · people with non‐transfusion‐dependent thalassemia
1 finding from 1 review
Responder analysis · people with non‐transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serum ferritin (ng/mL): mean change from baseline · people with non‐transfusion‐dependent thalassemia
1 finding from 1 review
LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline · people with non‐transfusion‐dependent thalassemia
1 finding from 1 review
Satisfaction with treatment · people with non‐transfusion‐dependent thalassemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: Discontinuations compared with placebo (low certainty).
1 finding from 1 review
AE: abnormal serum creatinine (post‐baseline) · people with non‐transfusion‐dependent thalassemia
It is very uncertain whether deferasirox changes AE: abnormal serum creatinine (post‐baseline) compared with placebo (very low certainty).
1 finding from 1 review
Participant satisfaction (very satisfied or satisfied) · people with transfusion‐dependent thalassemia
Deferasirox probably leads to higher satisfaction with treatment (very satisfied or satisfied):… compared with deferoxamine (moderate certainty).
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Adverse event: Isolated serum creatinine increase above upper limit of normal · people with transfusion‐dependent thalassemia
Deferasirox may leads to higher AE: investigations ‐ isolated serum creatinine increase above ULN compared with deferoxamine (low certainty).
1 finding from 1 review
Mortality at any time point · people with transfusion‐dependent thalassemia
1 finding from 1 review